Pharmaceuticals
Developers of branded and generic drugs. Value creation rests on R&D pipelines, patent lifecycles, regulatory approvals and pricing power versus payers.
| Unternehmen | Letzter Kurs | Kursänderung | Marktkapitalisierung | ||
|---|---|---|---|---|---|
|
|
|
Eli Lilly and Co
LLY
|
$967,93 |
-1,4%
|
$915,06 Mrd. |
|
|
|
Johnson & Johnson
JNJ
|
$224,2 |
+0,6%
|
$540,17 Mrd. |
|
|
|
Roche Holding AG
ROG
|
CHf324,9 |
-0,4%
|
$339,83 Mrd. |
|
|
|
Novartis AG
NOVN
|
CHf113,84 |
+0,1%
|
$282,33 Mrd. |
|
|
|
AstraZeneca PLC
AZN
|
GBX13.512 |
-0,1%
|
$282,73 Mrd. |
|
|
|
Merck & Co Inc
MRK
|
$113,11 |
+0,3%
|
$280,74 Mrd. |
|
|
|
Novo Nordisk A/S
NOVO B
|
kr282,95 |
-2,2%
|
$198,17 Mrd. |
|
|
|
Pfizer Inc
PFE
|
$26,3 |
+0,4%
|
$149,53 Mrd. |
|
|
|
Bristol-Myers Squibb Co
BMY
|
$57,38 |
+0,6%
|
$116,81 Mrd. |